SCHEMBL6500322

SCHEMBL6500322

CC(C)(C)NC(=O)OCC(c1ccc(N)cc1)c1csc(NC(=O)OC(C)(C)C)n1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 1/20 0.39
CCR2 P41597 3/20 0.36
PI4KB Q9UBF8 1/20 0.36
HDAC3 O15379 4/20 0.35
HDAC1 Q13547 3/20 0.35
HDAC2 Q92769 3/20 0.35
HDAC10 Q969S8 3/20 0.35
HDAC6 Q9UBN7 1/20 0.35
NCOR2 Q9Y618 1/20 0.35
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HDAC8 Q9BY41 2/20 0.34
RAD52 P43351 1/20 0.34
PTPRB P23467 1/20 0.34
LCK P06239 1/20 0.32
FFAR2 O15552 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6500319 0.78 SIRT1 (0.43) SIRT1CCR2PI4KBHDAC3HDAC1
SCHEMBL6683522 0.73 LMNA (0.39) SMN1; SMN2
SCHEMBL16021033 0.72 CA1 (0.44) SIRT1CCR2PI4KBHDAC3HDAC1
SCHEMBL11086559 0.72 CA1 (0.44) SIRT1CCR2PI4KBHDAC3HDAC1
SCHEMBL7472746 0.71 RAB9A (0.50) PI4KBHDAC3HDAC1HDAC2HDAC10
SCHEMBL28334812 0.71 PI4KB (0.42) SIRT1CCR2PI4KBHDAC3HDAC1
SCHEMBL10884920 0.71 SMN1; SMN2 (0.46) SIRT1CCR2PI4KBCA1CA2
SCHEMBL1796424 0.70 PI4KB (0.44) SIRT1CCR2PI4KBHDAC3HDAC1
SCHEMBL27488721 0.70 PI4KB (0.44) SIRT1CCR2PI4KBHDAC3HDAC1
SCHEMBL16748763 0.70 PI4KB (0.44) SIRT1CCR2PI4KBHDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 SIRT1 804/4885CCR2 210/4885PI4KB 1625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.